Details of the Drug Combination

General Information of Drug Combination (ID: DCZKJWP)

Drug Combination Name
F901318 Cyclosporin A
Indication
Disease Entry Status REF
Invasive Aspergillosis Phase 1 [1]
Component Drugs F901318   DM2CUS0 Cyclosporin A   DMUYKBZ
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL is unavailable

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of F901318
Disease Entry ICD 11 Status REF
Fungal infection 1F29-1F2F Phase 2 [2]
F901318 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Aspergillus Dihydroorotate dehydrogenase (Aspergillus DHODH) TTTSUI2 G5EB61_EMENI Inhibitor [13]
------------------------------------------------------------------------------------
Indication(s) of Cyclosporin A
Disease Entry ICD 11 Status REF
Adult acute monocytic leukemia N.A. Approved [3]
Bronchiolitis obliterans syndrome N.A. Approved [4]
Large granular lymphocytic leukemia 2A90.1 Approved [5]
Leukemia N.A. Approved [6]
Lupus nephritis 4A40.0Y Approved [7]
Myeloid leukaemia 2B33.1 Approved [8]
Psoriasis EA90 Approved [9]
Xerophthalmia 5B55.Y Approved [10]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 1 [11]
Corneal disease 9A78.Z Investigative [12]

References

1 ClinicalTrials.gov (NCT03095547) Drug/Drug Interactions With F901318
2 ClinicalTrials.gov (NCT03583164) Evaluate F901318 Treatment of Invasive Fungal Infections in Patients Lacking Treatment Options (FORMULA-OLS). U.S. National Institutes of Health.
3 Clinical and biological impact of ATP-binding cassette transporter activity in adult acute myeloid leukemia. Haematologica. 2023 Jan 1;108(1):61-68.
4 Bronchiolitis obliterans syndrome is associated with increased senescent lymphocytes in the small airways. J Heart Lung Transplant. 2021 Feb;40(2):108-119.
5 Rituximab for rheumatoid arthritis-associated large granular lymphocytic leukemia, a retrospective case series. Semin Arthritis Rheum. 2020 Oct;50(5):1109-1113.
6 Cyclosporin A protects JEG-3 cells against oxidative stress-induced apoptosis by inhibiting the p53 and JNK/p38 signaling pathways. Reprod Biol Endocrinol. 2020 Oct 12;18(1):100.
7 Efficacy and safety of Iguratimod as an add-on therapy for refractory lupus nephritis: A preliminary investigational study. Front Immunol. 2023 Mar 8;14:1062919.
8 Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol. 2024 Feb;11(2):e127-e135.
9 Pustular psoriasis. Cutis. 1993 Jan;51(1):29-32.
10 Cyclosporin A (CyA) in primary Sj?gren's syndrome: a double blind study. Ann Rheum Dis. 1986 Sep;45(9):732-5.
11 Why Choose Cyclosporin A as First-line Therapy in COVID-19 Pneumonia. Reumatol Clin. 2020 Apr 16;S1699-258X(20)30044-9.
12 Anti-inflammatory therapy of dry eye. Ocul Surf. 2003 Jan;1(1):31-6.
13 Effect of the Novel Antifungal Drug F901318 (Olorofim) on Growth and Viability of Aspergillus fumigatus. Antimicrob Agents Chemother. 2018 Jul 27;62(8):e00231-18.